Application Of Serum ProGRP In Clinical Diagnosis And Treatment Of Patients With Small Cell Lung Cancere

Background Primary lung cancer(lung cancer)is one of the most common malignant tumors in China.In 2017,the National Cancer Registry released the first place in China for the incidence and mortality of malignant tumors in China in 2012.Small cell lung cancer(SCLC)accounts for about20-25% of lung cancer.It is a highly invasive tumor with rapid progression,prone to distant metastasis,and poor prognosis.SCLC is sensitive to chemoradiotherapy,but many patients are prone to recurrence and metastasis after treatment.Progastrin-releasing peptide(Pro GRP)is a new tumor marker for SCLC and is currently used for early diagnosis of SCLC,but there are few studies on the usefulness of Pro GRP in the evaluation of SCLC staging,prognosis monitoring and other diseases' interference with it.Objective1.To detect Pro GRP values for different diseases and analyze the interference of other diseases on the diagnosis of SCLC2.To explore the clinical significance of serum Pro GRP value in staging and prognosis monitoring of SCLC patients.Methods A total of 4032 patients were admitted to a hospital from March 2015 to August 2017,determining serum Pro GRP concentrations of 144 patients with small cell lung cancer,1618 patients with the non-small cell lung tumor group,42 patients with benign lung tumors,231 with extrapulmonary malignant tumors,275 with extrapulmonary benign disease,1,402 with benign lung disease,and 320 healthy patients.To comparison of serum Pro GRP levels in patients with extensive and limited SCLC;to analysis and evaluation of Pro GRP values before and after treatment in patients with SCLC changes and the correlation of tumor size.Results1.Compared with healthy control group,U test shows P<0.05 in patients with renal failure and healthy controls,the lung non-small cell tumor group,lung benign tumor group,extrapulmonary malignant tumor group,intrapulmonary benign disease group conduct U test,showing P>0.05.2.Serum Pro GRP levels in small cell lung cancer group were higher than those in each group,U test shows P <0.05 in each group;prolonged Pro GRP values in patients with small cell lung cancer were higher than the limited period,U test shows P<0.05;Serum Pro GRP between before and after treatment in small cell lung cancer progression and remission groups,U-test shows P<0.05;Serum Pro GRP between before and after treatment in small cell lung cancer stable group,U-test shows P>0.05;Serum Pro GRP concentration and tumor mass in small cell lung cancer The size is consistent.Conclusions1.When using serum Pro GRP to diagnose SCLC,the effects of renal failure should be ruled out.2.Serum Pro GRP is a specific tumor marker of SCLC without the interference of renal failure.It can be used as an auxiliary basis for SCLC staging,monitoring prognosis,and evaluating clinical efficacy of important indicators.